司美格鲁肽与其他降糖药物治疗2型糖尿病的成本效果比较:系统综述与Meta分析
该系统综述与Meta分析纳入2019年以来45篇文献(119项比较),评估司美格鲁肽对比其他降糖药治疗2型糖尿病的成本效果。总体上司美格鲁肽在73.9%的比较中具优势或具成本效果,但结果因申办方类型、地区及模型假设而异。
要点
- 司美格鲁肽在73.9%的比较中具优势或具成本效果。
- 诺和诺德资助的比较均显示具优势或成本效果,非行业资助为50.0%,其他行业资助为0。
- 高收入国家及采用更宽视角、更长时限、较低贴现率的研究中成本效果更优。
核心结论
- 司美格鲁肽与其他降糖药相比总体具成本效果,但结果因研究申办方类型、地区和模型假设而异,需透明且情境敏感的经济学评价。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和成本效果分析注册库至2024年6月11日,纳入2019年以来45篇文章(119项比较),来自欧洲24篇、北美13篇、亚洲8篇(均来自中国)。
主要发现
- 司美格鲁肽在全部比较的73.9%中具优势或具成本效果。
- 诺和诺德资助的比较中司美格鲁肽全部具优势或具成本效果,非行业资助的比较中为50.0%,其他行业资助的比较中为0。
- 在高收入国家以及采用更宽视角、更长时限和较低贴现率的研究中,司美格鲁肽更具成本效果。
- 采用共同货币单位和50000美元支付意愿阈值转换后结果保持一致。
关键数值与推荐
- 纳入研究中93.3%采用终身时限,84.4%采用医疗保健视角,68.9%由行业资助。
- 大多数研究报告质量高(86.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 人口学信息不够详细,限制更细粒度分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Significant clinical efficacy has been shown for semaglutide in managing type 2 diabetes (T2D); however, its cost-effectiveness remains uncertain. PURPOSE: To systematically review existing evidence on cost-effectiveness of semaglutide versus other T2D medications. DATA SOURCES: PubMed, Embase, and the Cost-Effectiveness Analysis Registry (by 11 June 2024). STUDY SELECTION: A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8). DATA EXTRACTION: Study characteristics and model characteristics/inputs/results were extracted. Lifetime costs and quality-adjusted life-years were evaluated. Proportions for cost-effectiveness outcomes (dominant, cost-effective, not cost-effective) were calculated. Subgroup analyses by region, sponsor type, comparator type, and model assumptions were performed. In sensitivity analysis a standard willingness-to-pay threshold was applied. DATA SYNTHESIS: Of the articles included, 93.3% included adoption of a lifetime horizon and 84.4% a health care perspective and 68.9% were industry sponsored. For most studies reporting quality was high (86.7%). Overall, semaglutide was dominant/cost-effective in 73.9% of all comparisons. Notably, semaglutide was found to be dominant/cost-effective in all comparisons sponsored by Novo Nordisk versus in 50.0% of these funded by nonindustry sponsors and in none funded by other industry sponsors. Additionally, semaglutide was more cost-effective in high-income countries and in studies with adoption of a broader perspective, longer horizon, and lower discount rates. Results remained consistent with conversion with a common currency unit and willingness-to-pay threshold of US$50,000. LIMITATIONS: Less detailed demographic information for more granular analyses. CONCLUSIONS: Semaglutide is generally cost-effective compared with other glucose-lowering medications in evaluation against within-study willingness-to-pay thresholds; however, results varied by study sponsor type, region, and model assumptions, highlighting the need for transparent and context-sensitive economic evaluations.
引用
- Liu Z, Zeng B, Sun F, et al. Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis. Diabetes Care. 2025. PMID: 40392993. doi:10.2337/dc24-2241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。